Pharmaceutical Medical Affairs teams are expected to deliver scientifically rigorous, relevant and engaging education while managing increasingly complex evidence, multiple stakeholders and demanding timelines. Yet when specialist expertise or additional capacity is needed, expanding the delivery structure does not always solve the problem. What teams often need is an experienced medical education specialist who can interpret the science, recognise the educational need and translate complex evidence into meaningful education for healthcare professionals.
Without the right specialist input, even well-resourced programmes can become difficult to manage. Scientific messages may lose clarity, educational materials can become overly complex, and internal Medical Affairs teams may spend valuable time coordinating work rather than focusing on scientific strategy and stakeholder engagement. For organisations exploring alternatives to large CRO-led medical education teams, the real question is therefore not simply how much external capacity is available, but whether the right expertise is directly accessible when it matters.
Billev Pharma East provides specialist medical education services designed to complement and strengthen internal Medical Affairs capabilities. Our multidisciplinary experts combine scientific understanding with practical medical education experience to transform complex evidence into focused, credible and relevant educational programmes. Whether additional expertise is needed for a specific initiative or as an extension of your existing team, we provide specialist support tailored to your scientific objectives, therapeutic area and educational needs.
What should pharmaceutical companies do to build effective medical education?
Pharmaceutical companies should start by defining the educational need before deciding what content or activity to develop. This means identifying where healthcare professionals have genuine knowledge or practice gaps, what the programme should achieve and which audience needs to be reached. Educational objectives should then guide the scientific content, learning design and choice of format.
Companies also need to establish clear scientific ownership. Medical Affairs should determine which evidence is relevant, how it relates to current clinical practice and which scientific messages are essential for the intended audience. Content should remain current, evidence-based, appropriately referenced, balanced and objective, while the educational approach should reflect how healthcare professionals are expected to use the information in practice.
The required expertise and internal capacity should be assessed early as well. A company may have a strong Medical Affairs strategy but lack sufficient resources or specific scientific and educational expertise to translate that strategy into effective programmes. When an external medical education service is needed, companies should define which capabilities should remain internally and where specialist input can add the greatest value. This helps ensure that external support complements existing Medical Affairs expertise rather than creating unnecessary complexity. Finally, companies should consider how educational quality and impact will be assessed. Medical education should not end with content delivery; the programme should be designed around a defined educational purpose and provide a basis for understanding whether that purpose has been achieved.
How does Billev Pharma East provide medical education specialist support?
Billev Pharma East gives pharmaceutical companies access to experienced medical education specialists when additional scientific expertise is needed without expanding the internal team. We step in where Medical Affairs teams need focused support to move from complex evidence and defined educational objectives to clear, scientifically robust education for healthcare professionals.
Our specialists can take responsibility for the scientific work behind an educational initiative: reviewing and interpreting the available evidence, identifying the information most relevant to the intended audience, developing the scientific narrative and translating complex data into content that is easier to understand and use. This gives internal Medical Affairs professionals more capacity to retain oversight of the programme while reducing the scientific development workload behind its execution.
Depending on the project, this may involve building the scientific narrative, structuring evidence around defined learning objectives, developing or refining educational content and ensuring that complex scientific information remains accurate, relevant and understandable for the intended HCP audience.
Because our wider team includes medical, regulatory, pharmacovigilance and scientific communication expertise, the medical education specialist can also draw on relevant competencies when a project extends beyond education alone. Where broader strategic input is required, our medical education consulting expertise can further support the connection between scientific objectives, educational planning and programme development.
The result is focused access to the expertise needed to get the scientific work done—while your Medical Affairs team remains in control of its objectives, priorities and decisions.
What matters when considering alternatives to large CRO-led medical education teams?
When pharmaceutical companies consider alternatives to large CRO-led medical education teams, the starting point should be the type of expertise the programme actually requires. Not every medical education initiative needs a large delivery structure. Some projects depend much more on having the right scientific expertise available at the right stage.
Companies should therefore consider where specialist input will have the greatest impact. A programme involving complex or rapidly evolving evidence may require deeper scientific interpretation. A new therapeutic area may call for expertise that is not available internally. Other projects may already have clear strategic direction but need an experienced medical education specialist to turn that direction into scientifically coherent educational content.
The level of integration with the internal Medical Affairs team is equally important. Whether support is provided by an individual specialist, a medical education agency or another external delivery model, external expertise should fit into existing scientific governance rather than create a parallel structure. Responsibilities for scientific decisions, evidence interpretation, content development and review should be clear from the outset, allowing the external specialist to contribute where additional expertise is needed while Medical Affairs retains appropriate oversight.
The required model may also change throughout a programme. Specialist input can be particularly valuable during evidence assessment and scientific narrative development, while different resources may be required during implementation. Defining these needs before the project begins helps companies build a delivery model around the work itself rather than automatically around the size of an external team.
Ultimately, the question is not how many people can support the programme, but whether the right expertise is available to deliver the scientific and educational objective.
What should a medical education specialist bring to a pharmaceutical project?
A medical education specialist should bring more than additional capacity to a pharmaceutical project. The real value lies in being able to understand complex scientific evidence, determine what matters for the educational objective and translate that evidence into a clear learning experience for healthcare professionals.
This requires strong scientific judgement. Clinical data rarely arrive in a form that can simply be transferred into educational materials. Evidence must be reviewed in context, relevant findings identified and scientific messages structured without losing important limitations or nuances. The specialist should be able to distinguish information that is essential to the learning objective from detail that may increase complexity without improving understanding.
Educational thinking is equally important. The content should respond to an identified knowledge or practice need and be developed around what healthcare professionals should understand or be able to apply after the activity. This reflects established principles for high-quality medical education, where educational needs, intended outcomes, appropriate evidence and learning design are connected from the outset.
For pharmaceutical Medical Affairs teams, this combination is particularly valuable. The medical education specialist becomes the link between the underlying science and the educational experience, helping ensure that complex evidence is not simply communicated, but translated into content with a clear scientific purpose and practical relevance.
Ultimately, specialist value should be measured not by the volume of content produced, but by how effectively scientific evidence is turned into education that enables healthcare professionals to understand the scientific evidence and its relevance to clinical practice.
When should pharmaceutical companies involve a medical education specialist?
The right time to involve a medical education specialist is often before educational content is developed. Early specialist input can help ensure that the available evidence, identified educational need and intended learning outcomes are connected before decisions are made about individual materials or activities. This is particularly important because effective medical education should be built around genuine educational needs and clearly defined outcomes rather than around a predetermined format.
Specialist support can become especially valuable when a company is entering a new therapeutic area, preparing education around new or evolving clinical evidence, addressing a specific HCP knowledge gap or developing a programme that requires deeper scientific interpretation. It may also be needed when internal Medical Affairs teams have the strategic expertise and scientific oversight but insufficient capacity to perform the detailed evidence review and content development required to move the programme forward.
Timing matters when the evidence itself is complex. Bringing a medical education specialist into the project only after the scientific narrative and educational structure have already been fixed can limit the value that specialist expertise can provide. Earlier involvement allows the evidence to be assessed in context and the educational approach to develop around what healthcare professionals actually need to understand.
The objective is therefore not to outsource expertise by default. It is to identify the stages where specialist scientific and educational input can materially strengthen the programme and involve that expertise before avoidable gaps become embedded in the content.
How should the impact of medical education be evaluated?
The success of medical education should not be measured only by whether an activity was delivered on time or how many healthcare professionals participated. Evaluation should return to the educational need identified at the beginning of the programme and determine whether the intended learning outcomes were achieved.
This requires companies to define what success means before the educational activity is developed. Depending on the objective, evaluation may explore whether participants found the education relevant, whether their knowledge or understanding improved, or whether the programme supported greater confidence in applying scientific information in practice. The appropriate measure should therefore follow the educational objective rather than being added after delivery.
An experienced medical education specialist can help connect these elements from the outset. Educational needs, scientific content, learning design and intended outcomes should form one coherent process, allowing the programme to be developed with evaluation already in mind.
The findings should also inform what happens next. Outcomes can reveal where knowledge gaps remain, which aspects of the scientific content require further clarification and whether future education should address a different need or audience.
For pharmaceutical companies, this shifts the focus from producing educational activities to understanding whether those activities achieved their intended purpose. It also provides Medical Affairs teams with a stronger basis for refining future programmes and directing specialist resources where they can create the greatest educational value.
Get the right medical education expertise when you need it
Effective medical education depends on having the right scientific expertise behind the programme. An experienced medical education specialist can help turn complex evidence and defined educational needs into focused, relevant education while allowing internal Medical Affairs teams to retain strategic and scientific oversight.
For pharmaceutical companies that need additional specialist expertise without building a larger internal or external delivery structure, Billev Pharma East provides focused medical education support aligned with the needs of each project. Our experts can step in where additional scientific and educational input is needed and help move your programme from evidence to effective execution.
Looking for a medical education specialist for your next project? Contact Billev Pharma East to discuss how our experts can support your Medical Affairs team.
Sources: 1 – European Federation of Pharmaceutical Industries and Associations (EFPIA). EFPIA Code of Practice, 2 – EFPIA. The EFPIA Code, 3 – EFPIA. Aligning the European Pharmaceutical Industry on a quality approach for industry funded and led Lifelong Learning in Healthcare activities, 4 – European Medicines Agency (EMA). Resources for healthcare professionals.